NCT01420523View on ClinicalTrials.gov

Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy

PHASE2TerminatedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions

Human Immunodeficiency VirusLipohypertrophy

Interventions

DRUG

Raltegravir-Maraviroc

Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day

Trial Locations (1)

75013

Hôpital Pitié Salpétrière, Paris

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

ViiV Healthcare

INDUSTRY

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV